Topics

Melflufen Continues to Impress in Heavily Pretreated Myeloma, FDA Submission Coming Soon

10:30 EDT 26 Mar 2020 | OncLive

Melflufen in continued to show strong clinical activity in patients with triple-class refractory multiple myeloma, according to final topline results from the pivotal phase II HORIZON study.

Original Article: Melflufen Continues to Impress in Heavily Pretreated Myeloma, FDA Submission Coming Soon

NEXT ARTICLE

More From BioPortfolio on "Melflufen Continues to Impress in Heavily Pretreated Myeloma, FDA Submission Coming Soon"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...